AI driven platform LiVeritas has launched LiLii AI powered integrated laboratory platform and beta testing, signaling a strategic shift toward AI augmented workflows that can attract pharma clients seeking accelerated discovery, streamlined data management, and reduced cycle times in drug development.

MSaaS capability Mass Spec as a Service offers automated workflows and software tools to integrate MS data into preclinical and early clinical testing, presenting an upsell opportunity to biopharma partners aiming to enhance analytical throughput, data quality, and regulatory-ready documentation.

Speed to IND Curated analytical test packages focused on drug design optimization, process development, and IND readiness indicate a clear value proposition for startups and mid-sized biotechs seeking to de-risk and accelerate IND submissions with faster analytics and clearer CMC strategies.

Digital transformation Partner-centric software solutions for analytical operations, CMC strategies, and drug product knowledge management position LiVeritas as a provider of end-to-end data infrastructure, enabling customers to consolidate systems and improve collaboration across development teams.

Growth readiness Recent platform beta launches and a growing revenue footprint with a lean team suggest opportunities to target early-stage biotechs and contract research organizations looking for scalable, innovative analytical partners with the agility of a startup and the validation of industry expertise.